← Eichor
Study identifier: NCT04882904 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.

Condition: Amyotrophic Lateral Sclerosis  ·  Sponsor: Centre Hospitalier Universitaire de Liege

PhaseNA
Planned participants45
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

ActiSLA is a monocentric academic study. Patients with amyotrophic lateral sclerosis may be included on a voluntary basis. The investigators plan to include a group of approximately 20 patients with ALS. The investigators have planned to assess patient every three months for a year. On each visit, participants will undergo a clinical examination with MRC sum score and Ashworth scores. They will perform few tests ( 6-minutes walk test (6MWT), dynamometric measure, electromyography, Edinburgh Cognitive and Behavioural ALS Screen ) and will answer to some questionaires (dysphagia handicap scale, ALS-SFR-r). After each visit, participants will wear Actimyo for one month daily.

This description comes directly from the study's public registry record.

Talk to the study team

Laurie MEDARD  ·  43218222  ·  Laurie.Medard@citadelle.be

Always discuss trial participation with your own doctor first.

Locations (1)

CHR CitadelleLiège, Liège, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04882904